欧洲多国真实世界研究中TNF抑制剂与托珠单抗联合或不联合csDMARDs治疗生物制剂初治类风湿关节炎的疗效比较
该研究纳入7个欧洲注册中心2009至2016年起始TCZ或TNFi治疗的bDMARDs初治RA患者。调整协变量后,TCZ单药和联合用药的停药风险均低于TNFi联合csDMARDs,但CDAI随时间变化及流失校正后的LDA/缓解比例在各组间相似。
要点
- TCZ单药和联合用药的调整后停药风险低于TNFi联合csDMARDs。
- 各组间调整后CDAI随时间变化无显著差异。
- 流失校正后1年CDAI LDA和缓解比例在TCZ(联合或不联合csDMARDs)与TNFi联合组间相似。
核心结论
- 在7个欧洲国家的常规诊疗中,bDMARDs初治RA患者接受TNFi联合csDMARDs、TCZ联合csDMARDs或TCZ单药治疗,其调整后药物留存率、调整后CDAI随时间变化及流失校正后的应答比例相似。
研究设计与样本
- 基于7个欧洲注册中心的观察性队列研究,纳入2009至2016年起始TCZ或TNFi治疗的bDMARDs初治RA患者。
- 共纳入6713例TNFi联合csDMARDs、3762例TNFi单药、646例TCZ联合csDMARDs和384例TCZ单药患者。
- 采用Kaplan-Meier和Cox模型分析药物留存率,混合模型分析CDAI随时间变化,并对1年时CDAI低疾病活动度和缓解比例进行流失校正。
主要发现
- 粗中位留存时间:TNFi联合组3.67年(95%CI 3.41-3.83),TNFi单药组4.14年(3.77-4.62),TCZ联合组2.98年(2.76-3.34),TCZ单药组3.63年(3.34-5.03)。
- 调整协变量、国家和治疗起始年份分层后,与TNFi联合组相比,TCZ单药组停药风险比为0.60(95%CI 0.52-0.69),TCZ联合组为0.66(95%CI 0.54-0.81)。
- 调整后CDAI随时间变化在各组间无显著差异。
- 流失校正后1年CDAI低疾病活动度和缓解比例在TCZ联合或不联合csDMARDs与TNFi联合组间相似。
关键数值与推荐
- 药物留存率以中位留存时间(年)及停药风险比(95%CI)表示。
- 疾病活动度以CDAI评估,应答指标为CDAI低疾病活动度和缓解。
- 停药风险比调整了协变量、国家和治疗起始年份分层。
临床怎么用
- 对于bDMARDs初治RA患者,TCZ单药或联合csDMARDs与TNFi联合csDMARDs在药物留存、疾病活动度改善和应答比例方面相似。
- TCZ单药和联合用药的停药风险低于TNFi联合csDMARDs,但需结合流失校正后的应答比例综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab (TCZ) or TNF-inhibitor (TNFi) with (-combo) or without (-mono) conventional synthetic DMARDs (csDMARDs). METHODS: Patients with RA across 7 European registries, naïve to bDMARDs who initiated treatment with TCZ or TNFi from 2009 to 2016 were included. Drug retention rate was analyzed using Kaplan-Meier and Cox models, and CDAI over time by mixed models. The proportions of patients reaching CDAI low disease activity (LDA) and remission after one year were corrected for attrition. RESULTS: 6713 TNFi-combo, 3762 TNFi-mono, 646 TCZ-combo and 384 TCZ-mono were eligible. Crude median retention was 3.67 years (95%CI 3.41-3.83) for TNFi-combo, 4.14 (3.77-4.62) for TNFi-mono, 2.98 (2.76-3.34) for TCZ-combo and 3.63 years (3.34-5.03) for TCZ-mono. After adjustment for covariates, country and year of treatment initiation stratification, hazards of discontinuation were lower for TCZ-mono (0.60, 95% CI 0.52-0.69) and TCZ-combo (0.66, 95% CI 0.54-0.81) compared to TNFi-combo. Adjusted CDAI evolution was not significantly different between groups. CDAI LDA and remission corrected for attrition were similar between TCZ with or without csDMARDs and TNFi-combo. CONCLUSION: In routine care across 7 European countries, the adjusted drug retention, adjusted CDAI over time and attrition-corrected response proportion for RA patients were similar for bio-naïve patients if treated with TNFi-combo, TCZ-combo or TCZ-mono.
引用
- Lauper K, Mongin D, Iannone F, et al. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019. PMID: 31280937. doi:10.1016/j.semarthrit.2019.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。